Rankings
▼
Calendar
ALNY FY 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
ALNY
Alnylam Pharmaceuticals, Inc.
$43B
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2.2B
+23.0% YoY
Gross Profit
$1.9B
85.6% margin
Operating Income
-$177M
-7.9% margin
Net Income
-$278M
-12.4% margin
EPS (Diluted)
$-2.18
Cash Flow
Operating Cash Flow
-$8M
Free Cash Flow
-$43M
Stock-Based Comp.
$272M
Balance Sheet
Total Assets
$4.2B
Total Liabilities
$4.2B
Stockholders' Equity
$67M
Cash & Equivalents
$966M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2.2B
$1.8B
+23.0%
Gross Profit
$1.9B
$1.5B
+26.8%
Operating Income
-$177M
-$282M
+37.3%
Net Income
-$278M
-$440M
+36.8%
← Q4 2023
All Quarters
Q1 2024 →